Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | APAF1 | O14727 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | UBE2N | P61088 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminodimethoxyquinazolinylpiperazine SCHEMBL32690190 | 1.00 | KDM4E (1.00) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| Aminodimethoxyquinazolinylpiperazine SCHEMBL11079651 | 0.99 | POLB (0.97) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| SCHEMBL7796182 | 0.95 | KDM4E (0.90) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| Hydrochloric Acid SCHEMBL11475168 | 0.94 | POLB (0.88) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| SCHEMBL31187488 | 0.90 | KDM4E (0.82) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| SCHEMBL11165343 | 0.90 | KDM4E (0.81) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| Hydrochloric Acid SCHEMBL29393496 | 0.89 | POLB (0.80) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| SCHEMBL11869688 | 0.87 | KDM4E (0.78) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| SCHEMBL15218289 | 0.87 | KDM4E (0.76) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| SCHEMBL13191126 | 0.87 | KDM4E (0.76) | KDM4EAPAF1ALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| WO-2021086134-A1 | METHOD AND DETECTION KIT FOR DETECTING PATHOGENIC MICROORGANISMS USING NANOPORES | 한국생명공학연구원 | 2021-05-06 | — | — | WO | claimed |
| EP-2421857-B1 | PROCESS FOR THE PREPARATION OF DOXAZOSIN AND SALTS THEREOF | CIPLA LTD (IN) | 2013-08-28 | — | — | EP | claimed |
| US-8426590-B2 | Process for the preparation of doxazosin and salts thereof | CIPLA LIMITED (IN) | 2013-04-23 | — | — | US | claimed |
| EP-2421857-A2 | Process for the preparation of doxazosin and salts thereof | CIPLA LIMITED (IN) | 2012-02-29 | — | — | EP | claimed |
| US-20120041199-A1 | Process for the Preparation of Doxazosin and Salts Thereof | CIPLA LIMITED (IN) | 2012-02-16 | — | — | US | claimed |
| WO-2010109185-A2 | PROCESS FOR THE PREPARATION OF DOXAZOSIN AND SALTS THEREOF | CIPLA LIMITED (IN) | 2010-09-30 | — | — | WO | claimed |
| WO-2005087742-A1 | METABOLIC KINASE MODULATORS AND METHODS OF USE AS PESTICIDES | EXELIXIS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| EP-0536329-B1 | R(+)-TERAZOSIN | ABBOTT LAB (US) | 1996-04-17 | — | — | EP | claimed |
| EP-0146642-B1 | PROCESS FOR THE PREPARATION OF 4-AMINO-6,7-DIMETHOXY-2-(4-(FUROYL-2)-PIPERAZIN-1-YL)-QUINAZOLINE AND ITS PHYSIOLOGICALLY ACCEPTABLE SALT | LUDWIG HEUMANN & CO GMBH (DE) | 1988-01-20 | — | — | EP | claimed |
| EP-0146642-A1 | Process for the preparation of 4-amino-6,7-dimethoxy-2-(4-(furoyl-2)-piperazin-1-yl)-quinazoline and its physiologically acceptable salt | LUDWIG HEUMANN & CO GMBH (DE) | 1985-07-03 | — | — | EP | claimed |
| JP-56063967-A | — | — | None | — | — | JP | disclosed |
| JP-4029981-A | — | — | None | — | — | JP | disclosed |
| JP-56077265-A | — | — | None | — | — | JP | disclosed |
| US-12560588-B2 | High-efficiency screening method for RNA-targeting drugs using nanopores | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2026-02-24 | — | — | US | disclosed |
| US-4062844-A | Process for preparing hypotensive 2-(4-aroylpiperazin-1-yl)-amino-6,7-dimethoxyquinazolines | PFIZER INC. (US) | 1977-12-13 | — | — | US | disclosed |
| US-4060615-A | ANTIHYPERTENSIVE, PHOSPHODIESTERASE INHIBITOR | MEAD JOHNSON & COMPANY (US) | 1977-11-29 | — | — | US | disclosed |
| US-4001238-A | HYPOTENSIVES | BRISTOL-MYERS COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
| US-4001237-A | HYPOTENSIVES | BRISTOL-MYERS COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
| US-3980650-A | 4-Amino-pyrimidine derivatives | N.V. KONINKLIJKE PHARMACEUTISCHE FABRIEKEN V/H BROCADES-STHEEMAN EN PHARMACIA (NL) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041199-A1 | Process for the Preparation of Doxazosin and Salts Thereof | REN, QDPR, ACE | KDM4E 1390/4885APAF1 3758/4885ALDH1A1 638/4885 |
| US-12560588-B2 | High-efficiency screening method for RNA-targeting drugs using nanopores | ABCB1, NSUN3, TRDMT1 | KDM4E 1675/4885APAF1 1182/4885ALDH1A1 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.